Copyright © 2002 by the European Society of Cardiology.
Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty
Division of Cardiology, Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland
revised August 13, 2001; accepted August 15, 2001
Abstract
Aims Restenosis after percutaneous coronary angioplasty remains an important limitation of this procedure. This study evaluates whether elevated total plasma homocysteine levels contribute to the development of restenosis after coronary angioplasty.
Methods and Results Two hundred and five patients were recruited after successful angioplasty of at least one coronary stenosis (
50%). End-points were restenosis (50%) and a composite of major adverse cardiac events. Of the 205 patients, 183 (89·3%) underwent 6 months angiographic follow-up. Patients with restenosis had significantly higher homocysteine levels than those without (10·9± 3·9µmol.l–1 vs 9·3±3·8µmol.l–1, P<0·01). Homocysteine levels were significantly correlated to follow-up diameter stenosis (r=0·24, P=0·0001), especially in small vessels (<3mm) treated with balloon angioplasty only (r=0·40,P <0·0005). Late lumen loss at follow-up was significantly smaller with homocysteine levels below 9µmol.l–1 (0·62±0·82mm vs 0·90±0·77mm, P<0·01). Restenosis rate (25·3% vs 50·0%,P <0·001) and major adverse cardiac events (15·7% vs 28·4%,P <0·05) were also significantly lower in patients with homocysteine levels below 9µmol.l–1. Multivariate analysis did not weaken these findings.
Conclusion Total plasma homocysteine is a strong predictor of restenosis and major adverse cardiac events after coronary angioplasty. Thus, plasma homocysteine appears to be an important cardiovascular risk factor influencing outcome after successful coronary angioplasty.
Key Words: Angioplasty, death, homocysteine, myocardial infarction, restenosis
f1 Correspondence: Guido Schnyder, MD, UCSD Medical Center-MC 8784, Cardiology Division, 200 West Arbor Drive, San Diego, CA 92103, U.S.A.
References
- Serruys PW, Luijten HE, Beatt KJ. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361–371
[Abstract/Free Full Text] - N Engl J Med. 1997;336:1689–1696
[Abstract/Free Full Text] - Tardif JC, Cote G, Lesperance J. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997;337:365–372
[Abstract/Free Full Text] - Tsuchikane E, Fukuhara A, Kobayashi T. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21–26
[Abstract/Free Full Text] - Kiesz RS, Buszman P, Martin JL. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). Circulation. 2001;103:26–31
[Abstract/Free Full Text] - Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
[Abstract/Free Full Text] - Seshadri N, Robinson K. Homocysteine, B vitamins, and coronary artery disease. Med Clin North Am. 2000;84:215–237[CrossRef][Web of Science][Medline]
- Chao CL, Tsai HH, Lee CM. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis. 1999;147:379–386[CrossRef][Web of Science][Medline]
- Schnyder G, Pin R, Roffi M, Flammer Y, Hess OM. Association of plasma homocysteine with the number of major coronary arteries severely narrowed. Am J Cardiol. 2001;88:7–10
- Tsai JC, Perrella MA, Yoshizumi M. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369–6373
[Abstract/Free Full Text] - Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis. 1998;136:169–173[CrossRef][Web of Science][Medline]
- Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2074–2081
[Abstract/Free Full Text] - Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 1997;95:1119–1121
[Abstract/Free Full Text] - Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370–1376[Web of Science][Medline]
- Wang XL, Duarte N, Cai H. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis. 1999;146:133–140[CrossRef][Web of Science][Medline]
- Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation. 1998;98:196–199
[Free Full Text] - Ubbink JB, Hayward-Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991;565:441–446[Web of Science][Medline]
- Genest JJ Jr, McNamara JR, Upson B. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991;11:1129–1136
[Abstract/Free Full Text] - Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98:2520–2526
[Abstract/Free Full Text] - Miner SE, Hegele RA, Sparkes J. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J. 2000;140:272–278[CrossRef][Web of Science][Medline]
- Morita H, Kurihara H, Kuwaki T. Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb Haemost. 2000;84:27–31[Web of Science][Medline]
- Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909–1916[Web of Science][Medline]
- Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895–901
[Abstract/Free Full Text] - Hajjar KA, Mauri L, Jacovina AT. Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem. 1998;273:9987–9993
[Abstract/Free Full Text] - Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327–1333
[Abstract/Free Full Text] - Hirshfeld JW Jr, Schwartz JS, Jugo R. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol. 1991;18:647–656[Abstract]
- Erbel R, Haude M, Hopp HW. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. N Engl J Med. 1998;339:1672–1678
[Abstract/Free Full Text] - Lincoff AM, Califf RM, Moliterno DJ. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999;341:319–327
[Abstract/Free Full Text] - Briguori C, Nishida T, Adamian M. Coronary stenting versus balloon angioplasty in small coronary artery with complex lesions. Catheter Cardiovasc Interv. 2000;50:390–397[CrossRef][Web of Science][Medline]
- Teirstein PS, Massullo V, Jani S. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697–1703
[Abstract/Free Full Text] - Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol. 1996;77:759–761[CrossRef][Web of Science][Medline]
- BMJ. 1998;316:894–898
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. K. Song, Y.-J. Son, and T. A. Lennie Trait Anger, Hostility, Serum Homocysteine, and Recurrent Cardiac Events After Percutaneous Coronary Interventions Am. J. Crit. Care., November 1, 2009; 18(6): 554 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Marcucci, D Brogi, F Sofi, C Giglioli, S Valente, A Alessandrello Liotta, M Lenti, A M Gori, D Prisco, R Abbate, et al. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting Heart, March 1, 2006; 92(3): 377 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brasselet, R. Garnotel, A. Lafont, S. Perotin, F. Vitry, E. Durand, L. Ducher, J. Elaerts, D. Metz, and P. Gillery Prepercutaneous Coronary Intervention Plasma Homocysteine Concentration Is a Useful Predictor of Angioplasty-Induced Myocardial Damage Clin. Chem., December 1, 2005; 51(12): 2374 - 2377. [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. Gregorio, H. Lange, and M. Chiariello Homocysteine and Its Effects on In-Stent Restenosis Circulation, November 8, 2005; 112(19): e307 - e311. [Full Text] [PDF]
|
|
|
|
|
|
C-K Wong, C J K Hammett, R The, J K French, W Gao, B J Webber, J M Elliott, A W Hamer, J A Ormiston, M W I Webster, et al. Lack of association between baseline plasma homocysteine concentrations and restenosis rates after a first elective percutaneous coronary intervention without stenting Heart, November 1, 2004; 90(11): 1299 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lange, H. Suryapranata, G. De Luca, C. Borner, J. Dille, K. Kallmayer, M. N. Pasalary, E. Scherer, and J.-H. E. Dambrink Folate Therapy and In-Stent Restenosis after Coronary Stenting N. Engl. J. Med., June 24, 2004; 350(26): 2673 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, G. Ndrepepa, J. Mehilli, S. Braun, M. Burghartz, H. Lengnick, K. Kolling, A. Schomig, and A. Kastrati Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2229 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-M. Lu, Y.-A. Ding, S.-J. Lin, W.-S. Lee, and H.-C. Tai Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention Eur. Heart J., November 1, 2003; 24(21): 1912 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matetzky, D. Freimark, S. Ben-Ami, I. Goldenberg, J. Leor, R. Doolman, I. Novikov, M. Eldar, and H. Hod Association of Elevated Homocysteine Levels With a Higher Risk of Recurrent Coronary Events and Mortality in Patients With Acute Myocardial Infarction Arch Intern Med, September 8, 2003; 163(16): 1933 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, Y. Flammer, M. Roffi, R. Pin, and O. M. Hess Plasma homocysteine levels and late outcome after coronary angioplasty J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1769 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Schnyder, M. Roffi, Y. Flammer, R. Pin, and O. M. Hess Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Clinical Outcome After Percutaneous Coronary Intervention: The Swiss Heart Study: A Randomized Controlled Trial JAMA, August 28, 2002; 288(8): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||